A Northbrook-based maker of an oral testosterone product is planning an initial public offering of 5 million of its shares at an expected price of $11 to $13 a share, according to a filing Monday with the Securities and Exchange Commission. Get the full story »
Thomas McNerney
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
